April 7, 2005WALLACE PHARMACEUTICALS(n/k/a MEDPOINTEPHARMACEUTICALS),Petitioner,v.
ILLINOIS ENVIRONMENTAL
PROTECTION AGENCY,Respondent.
During Wallace’s production process, several of the tablet products use
a wet granulation process.
35 Ill.
Adm.
Code 215.482(a).
MedPointe expected the accelerated production and increased demand from three newproduct lines beginning in October 2002 to cause the facility to exceed the thresholds of Section215.480(a) and become subject to the Section 215.482(a) control requirements. Under all of these circumstances, the Board concluded that MedPointehas demonstrated that denial of variance would impos...
Allowed
Adobe Portable Document Format (.pdf) - application/pdf
PCB 02-207 Supplemental Opinion and Order 040705.pdf
... 
